Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-label, Blinded Endpoint, Comparative Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

NCT06929806 is registered in ClinicalTrials.gov with Pharmacosmos A/S as lead sponsor.

NCT NCT06929806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06929806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-label, Blinded Endpoint, Comparative Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
Lead sponsor
Pharmacosmos A/S
Phase
Phase 3
Overall status
Recruiting
Start date
May 1, 2025
Completion date
December 1, 2027
Enrollment
1,900 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure, iron deficiencies